Stemline Therapeutics

Company Overview

Stemline Therapeutics, Inc. (“Stemline”) a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. Our dedicated team of scientists, specialists, researchers, and developers are committed to providing transformational oncology treatments to those who need it, with the ultimate goal of improving the lives of those impacted by cancer.

Mission/Beliefs/Values

To build a leading commercial stage biopharmaceutical company focused on improving the lives of cancer patients by developing and marketing innovative oncology therapeutics that target difficult-to-treat cancers.

Hematologic Cancer

BPDCN is a cancer that affects your blood and the soft tissue inside your bones, which is called bone marrow. It can also affect other parts of your body, such as your lymph nodes, spleen, central nervous system, and skin. Learn more about this hematologic disease at http://BPDCNinfo.com.

Learn More

Metastatic Breast Cancer

Nearly 1 out of 2 people with ER+/HER2- metastatic breast cancer may develop an ESR1 mutation after progression on hormone therapy. Learn more about this ESR1 mutation at http://Knowesr1.com.

Learn More